跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 85,751 条关于
“EMPOWER-Lung 1”
全部
85,751
临床试验
58,990
药物
7,455
机构
1,456
资讯
17,850
去年
Landmark NSCLC Studies of 2024: LAURA, EMPOWER-Lung 1, and Beamion LUNG-1 Trials Show Promise
去年
Cemiplimab Shows Significant Survival Benefit in NSCLC Patients with Brain Metastases and High PD-L1 Expression
2年前
Libtayo Demonstrates Durable Survival Benefit in Advanced NSCLC After Five Years
10个月前
Libtayo Gains Widespread Provincial Reimbursement Across Canada for Advanced NSCLC and Basal Cell Carcinoma
3年前
FDA Approves Regeneron's Libtayo Combination for Non-Small-Cell Lung Cancer Treatment
去年
AbbVie's Emraclidine Fails to Meet Primary Endpoints in Phase 2 Schizophrenia Trials
17天前
BC Platforms Launches BC Mosaic App Store to Empower Data Scientists and Healthcare Researchers
去年
EMPOWER CAD Study Confirms Benefits of IVL-First Strategy in Female Patients with Calcified Coronary Lesions
29天前
Digital eMPower program reduces anxiety and depression in adults with chronic conditions, with self-directed delivery matching human-supported outcomes
去年
Regeneron's Libtayo Combination Therapy Demonstrates 19.4% Five-Year Survival Rate in Advanced Lung Cancer
第 1 页,共 1785 页
上一页
下一页